Develops drug therapies that use immune cells to deliver treatments to brain tumors and other tissues, for patients with brain cancers and other conditions.
10-K for FY2025, filed Apr 1, 2026We are a biopharmaceutical company pioneering a transformational approach to enhance the transfer of therapeutics into the brain…View ↗
We are closely working with researchers at Duke University to translate preclinical proof of concept data of its first proprietary platform…View ↗
The first application of our technology is APTN-101, a proprietary epidermal growth factor receptor variant III, or EGFRVIII, BRiTE in…View ↗
No revenue reported yet.
10-K for FY2025, filed Apr 1, 2026
10-Q for Q2 FY2026, filed Aug 13, 2026
−$1.2MView ↗
Competes with Context Therapeutics, Vir Biotechnology, Janux Therapeutics, Amgen, and Genentech
10-K for FY2025, filed Apr 1, 2026The pharmaceutical industry is highly competitive and characterized by intense and rapidly changing competition to develop new technologies…View ↗
Loading...
